Mereo BioPharma appoints new head of patient access
Updated : 15:15
Multi-asset biopharmaceutical company Mereo BioPharma Group announced the appointment of Wills Hughes-Wilson as head of patient access and commercial planning on Monday.
The AIM-traded firm said that in her role, Hughes-Wilson would be responsible for leading and optimizing Mereo's patient access and commercialisation strategies, initially in a part-time role as the company built out its rare disease commercial infrastructure.
“Ms. Hughes-Wilson brings in-depth market access and product launch expertise as well as a proven ability to develop and lead commercial planning efforts globally,” said Mereo CEO Dr Denise Scots-Knight.
“With extensive experience in the rare and orphan disease areas, Ms Hughes-Wilson will be instrumental as we advance our portfolio of rare product candidates through late-stage clinical development and towards commercialization.
“We are very pleased to welcome her and believe she will be a strong complement to our existing leadership team at Mereo.”
Most recently, Hughes-Wilson served on the executive leadership team as chief patient access officer and senior vice president of access and external affairs at Swedish Orphan Biovitrum (Sobi).
In her role, Hughes-Wilson was responsible for Sobi's go-to-market commercialisation approach and led the pricing, reimbursement and access teams for Sobi's rare disease product portfolio.
Prior to joining Sobi, Hughes-Wilson served as vice president of health and market access policy at Genzyme Corporation - now part of Sanofi.
"I am thrilled to join Mereo's leadership team at such a pivotal time for the company," Hughes-Wilson stated.
"Mereo's robust portfolio of product candidates, including BPS-804 for the treatment of osteogenesis imperfecta and AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency, has the potential to address significant unmet medical needs in rare diseases.
“I look forward to applying my experience to help the Company continue its journey to develop these therapies and, if approved, make them commercially available to patients and healthcare systems in a timely and sustainable manner.”